Abstract
In vitro activities of methanol and water (crude) extracts of leaves, barks and seeds from Cassia fistula were tested against Gram-positive and Gram-negative bacteria by using disc-diffusion method at 6.25-100 μg/μl. Of which water extracts of leaf showed powerful antibacterial action against Proteus vulgaris and Staphylococcus aureus than others. Six (6) purified compounds from the most active leaves displayed higher antibacterial activity than the compound (2) and (4) against P. vulgaris and S. aureus. In vitro toxicological properties were evaluated by MTT assay to test the reduction of viability of human lung (MRC-5), skin (HEPK) fibroblasts and human macrophage (U-937) cells with the C. fistula water-leaf extracts and compounds (6) at 62.5 - 2000 μg/ml doses. The water-leaf extracts -showed less cytotoxic activity on MRC-5 cells than the U-937 and HEPK cells. However, the compound (6) was not toxic to all the human cells up to 1000 μg/ml doses. In conclusion, the significant antibacterial activity may be due to the compound flavonoids and the toxicity results proved the traditional usage of this plant for bacterial therapy.
Keywords: Cassia fistula, Konraikki, Compounds, Antibacterial activity, Cytotoxicity, Human cells
Letters in Drug Design & Discovery
Title:Purification and Biological Evaluation of Some Bioactive Metabolomics as Antimicrobial Agent
Volume: 10 Issue: 5
Author(s): Ramar Perumal Samy, Gautam Sethi and Vincent T.K Chow
Affiliation:
Keywords: Cassia fistula, Konraikki, Compounds, Antibacterial activity, Cytotoxicity, Human cells
Abstract: In vitro activities of methanol and water (crude) extracts of leaves, barks and seeds from Cassia fistula were tested against Gram-positive and Gram-negative bacteria by using disc-diffusion method at 6.25-100 μg/μl. Of which water extracts of leaf showed powerful antibacterial action against Proteus vulgaris and Staphylococcus aureus than others. Six (6) purified compounds from the most active leaves displayed higher antibacterial activity than the compound (2) and (4) against P. vulgaris and S. aureus. In vitro toxicological properties were evaluated by MTT assay to test the reduction of viability of human lung (MRC-5), skin (HEPK) fibroblasts and human macrophage (U-937) cells with the C. fistula water-leaf extracts and compounds (6) at 62.5 - 2000 μg/ml doses. The water-leaf extracts -showed less cytotoxic activity on MRC-5 cells than the U-937 and HEPK cells. However, the compound (6) was not toxic to all the human cells up to 1000 μg/ml doses. In conclusion, the significant antibacterial activity may be due to the compound flavonoids and the toxicity results proved the traditional usage of this plant for bacterial therapy.
Export Options
About this article
Cite this article as:
Perumal Samy Ramar, Sethi Gautam and T.K Chow Vincent, Purification and Biological Evaluation of Some Bioactive Metabolomics as Antimicrobial Agent, Letters in Drug Design & Discovery 2013; 10 (5) . https://dx.doi.org/10.2174/1570180811310050011
DOI https://dx.doi.org/10.2174/1570180811310050011 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Biological Evaluation of Amino Acid Based Mutual Amide Prodrugs of Phenytoin as Anticonvulsant Agents
Central Nervous System Agents in Medicinal Chemistry Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) From Discovery to the Coming Generation of Histone Deacetylase Inhibitors
Current Medicinal Chemistry Pharmacogenetic Approach to Treating Drug Dependence: Serotonin Transporter Gene (SLC6A4) Promoter Polymorphisms as Treatment Predictors in Jordanian Arabs
Current Pharmacogenomics and Personalized Medicine Synthesis and Anticonvulsant Activity of Some Novel 2-Methyl Imidazole Derivatives
Letters in Drug Design & Discovery Microendophenotypes of Psychiatric Disorders: Phenotypes of Psychiatric Disorders at the Level of Molecular Dynamics, Synapses, Neurons, and Neural Circuits
Current Molecular Medicine Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy
Current Genomics Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives
Central Nervous System Agents in Medicinal Chemistry Tactile Angle Discrimination Decreases due to Subjective Cognitive Decline in Alzheimer’s Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Neuropharmacology The AMPAR Antagonist Perampanel Regulates Neuronal Necroptosis via Akt/GSK3β Signaling After Acute Traumatic Injury in Cortical Neurons
CNS & Neurological Disorders - Drug Targets Understanding Membrane Protein Drug Targets in Computational Perspective
Current Drug Targets Brain Hyperthermia During Physiological and Pathological Conditions: Causes, Mechanisms, and Functional Implications
Current Neurovascular Research Serotonin<sub>2c</sub> Receptor Constitutive Activity: In vivo Direct and Indirect Evidence and Functional Significance
Central Nervous System Agents in Medicinal Chemistry Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Alzheimer’s Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Current Alzheimer Research Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued)